Vaccines: latest news

Vaccines resources

  • Vaccines

    HIV vaccine researchers are still looking for a vaccine that would offer a significant degree of protection against HIV infection....

    From: Preventing HIV

    Information level Level 4
  • Vaccines

    The promise of an effective HIV vaccine has always been just over the horizon, but more than 20 years after the identification of HIV, vaccines...

    From: HIV transmission & testing

    Information level Level 4

Vaccines features

Vaccines news from aidsmap

More news

Vaccines news selected from other sources

  • Inovio HIV Vaccine Elicits Nearly 100% Immune Response Rates in a Clinical Study

    Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that its HIV vaccine, PENNVAX®-GP, produced amongst the highest overall levels of immune response rates (cellular and humoral) ever demonstrated in a human study by an HIV vaccine.

    24 May 2017 | Inovio press release
  • Why the world needs an HIV vaccine

    On HIV Vaccine Awareness Day, UNAIDS is calling for continued research to find a vaccine for HIV. 

    18 May 2017 | UNAIDS
  • Stock market models accurately predict changes in HIV over time

    Stock market models accurately predict changes in HIV over timeHealioMathematical models that were originally developed to predict changes in stock prices accurately predicted changes in the properties of HIV, suggesting that such models could be used for the development of a future vaccine for HIV, according to data published in PLOS Biology.

    18 May 2017 | Healio
  • Three countries get first malaria vaccine

    The world's first vaccine against malaria will be introduced in three countries - Ghana, Kenya and Malawi - starting in 2018. The four-shot vaccine should prevent four in 10 cases of the disease.

    24 April 2017 | BBC
  • Vaccine trial: Community trust is key

    Dr. Linda-Gail Bekker knows from more than 20 years in the field that researchers have to work hand in hand with the communities most affected if they want to halt an epidemic. And the townships are ground zero for HIV/AIDS in Cape Town.

    17 February 2017 | Fred Hutch
  • New and Touted HIV bNAb: Big deal or news blip?

    Fervid research has uncovered dozens of antibodies that shield cells from HIV. Much work suggests broadly neutralizing antibodies hold promise as keys to HIV vaccine design or as immune therapy delivered by passive immunization or viral vectors. So what inspired the media handstands proclaiming the discovery of yet another bNAb?

    25 January 2017 | AVAC
  • Successful antibody trial in HIV-infected individuals

    A research team led by investigators of the Rockefeller University in New York and Prof Florian Klein, University Hospital Cologne and German Center for Infection Research, has tested a new HIV neutralizing antibody, called 10-1074, in humans. The results of the trial have just been published in Nature Medicine.

    17 January 2017 | Eurekalert Inf Dis
  • J&J vaccine plus Gilead immune booster shows promise as HIV fighter

    An experimental HIV vaccine from Johnson & Johnson combined with an immune system booster from Gilead Sciences Inc showed promise at keeping the virus at bay in monkeys even after treatments had stopped, marking yet another step toward the development of a so-called functional cure for HIV.

    10 November 2016 | Reuters
  • Pneumococcal infections decrease in patients with suppressed HIV

    Pneumococcal infections among patients with virologically suppressed HIV decreased significantly in recent years, according to data from a retrospective, case-controlled study.

    08 November 2016 | Healio
  • Explainer: the how, what and why of the latest HIV vaccine trial

    As the global quest for an HIV vaccine continues, Linda-Gail Bekker explains the significance of the latest large-scale trial underway in South Africa.

    01 November 2016 | The Conversation
More news

Our information levels explained

  • Short and simple introductions to key HIV topics, sometimes illustrated with pictures.
  • Expands on the previous level, but also written in easy-to-understand plain language.
  • More detailed information, likely to include medical and scientific language.
  • Detailed, comprehensive information, using medical and specialised language.
Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.